NEW YORK (GenomeWeb News) – Cancer Genetics today said that it was awarded $1.8 million from New Jersey's Technology Business Tax Certificate Transfer program.

The program allows technology and biotechnology businesses with net operating losses to sell their unused net operating loss carryover and unused R&D tax credits for at least 80 percent of the value of the tax benefits to a profitable corporate taxpayer in New Jersey that is not an affiliated business. The $1.8 million awarded to Cancer Genetics is net of transaction costs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.